Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | CLL: IgHV mutational status

Nicolas Martinez-Calle • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Nicolas Martinez-Calle, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, outlines what he believes to be the most influential findings in chronic lymphocytic leukemia (CLL) research, specifically mentioning the use of IgHV mutational status in the personalization of CLL therapy This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Nicolas Martinez-Calle

3:17
Treating CLL in the UK: current and future outlooks
Nicolas Martinez-Calle • 11 Jun 2023
2:40
EPIC update: observational study of first-line acalabrutinib treatment for CLL
Nicolas Martinez-Calle • 11 Jun 2023
6:28
Outcomes following first-line therapy in routine clinical practice in ALCL
Nicolas Martinez-Calle • 14 May 2020
9:35
Outcomes of older patients with primary CNS lymphoma
Nicolas Martinez-Calle • 14 May 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals